Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Alector, Inc. (ALEC)

$1.50 +2.04% NASDAQ: ALEC · 15-min delayed
  • SOUTH SAN FRANCISCO, California
  • Public · NASDAQ: ALEC
  • 103 employees
$181.5MMarket cap
$21.0MRevenue · FY2025
-$142.9MNet income
103Employees
ALECNASDAQ
2019IPO

About Alector, Inc.

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$21.0M
Net income
-$142.9M
Total assets
$293.2M
Market cap
$181.5M
Operating margin
-741.3%
Net margin
-679.2%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$21.0M
Operating expenses
$177.1M
Operating income
-$156.0M
Income tax
$168.0K
Net income
-$142.9M
EPS (basic)
$-1.39
EPS (diluted)
$-1.39

Balance sheet

Total assets
$293.2M
Current assets
$266.5M
Total liabilities
$262.6M
Current liabilities
$69.5M
Shareholders’ equity
$30.6M

Cash flow

Operating cash flow
-$184.0M
Investing cash flow
$196.6M
Financing cash flow
$20.2M
Net cash flow
$32.8M

Statements via Polygon.io (SEC filings)

NASDAQ: ALEC
$1.50 +2.04%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.14 $3.32

52-week range

Market cap
$181.5M
EPS (diluted)
$-1.39
Shares outstanding
121.0M
Open
Day range
Prev close
Volume
IPO date
Feb 7, 2019

Alector, Inc. (ALEC) Stock Price

  • Reported a net loss of $142.9M in FY2025.
  • Revenue declined 90% from FY2021 to FY2025.
  • Trading 55% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Alector, Inc..

Write a review
Newsroom

News about Alector, Inc.

News & sentiment via Polygon.io

FAQ

Alector, Inc.: frequently asked questions

Is Alector, Inc. an American company?

Alector, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Alector, Inc. headquartered?

Alector, Inc. is headquartered in South San Francisco, California, United States.

Is Alector, Inc. publicly traded?

Yes — Alector, Inc. is a publicly traded company. Its stock trades under the ticker symbol ALEC on the NASDAQ.

What does Alector, Inc. do?

Alector, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →